華康生物醫學：2018年報.pdf

1、(incorporated in the Cayman Islands with limited liability)(於開曼群島註冊成立之有限公司)Stock Code 股份代號:8622ANNUALREPORTHuakang Biomedical Holdings Company Limited華康生物醫學控股有限 公 司年 報Huakang Biomedical Holdings Company Limited華康 生物醫學控股有限公司2018ANNUAL REPORT 2018 年報Huakang Biomedical Holdings Company Limited 華 康 生 物

2、醫 學 控 股 有 限 公 司CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED(THE“STOCK EXCHANGE”)香港聯合交易所有限公司（聯交所）GEM之特色GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the St

3、ock Exchange.Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and

4、other sophisticated investors.Given the emerging nature of companies listed on GEM,there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid mark

5、et in the securities traded on GEM.Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this annual report(the“Report”),make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoev

6、er arising from or in reliance upon the whole or any part of the contents of the Report.This Report,for which the Directors(the“Directors”)of Huakang Biomedical Holdings Company Limited(the“Company”,and together with its subsidiaries,the“Group”,“we”or“our”)collectively and individually accept full r